Abstract Tumour angioneogenesis is associated with the reexpression of oncofetal Wbronectin (oncFn) and tenascin-C (oncTn-C) splice variants, which may serve as targets for antibody-based pharmacodelivery. Knowledge of the vascular distribution and organization in diVerent tumours is of importance for the understanding of tumour vessel formation and might be crucial for therapy. Therefore, human SIP format antibodies against Fn ED-A, Fn ED-B and Tn-C A and C splice domains were used for immunoXuorescence labelling in renal, lung, oral, colon, breast and urinary bladder carcinoma specimens and in a renal carcinoma xenograft. The spatial relation to stroma, vessels and vascular basement membrane (vBM) was analysed including CD31 and laminin 4 chain antibodies. Renal cell carcinomas and atypical carcinoid of the lung revealed vessel-restricted oncFn and/or oncTn-C depositions; all other entities showed a variable stroma positivity including vessels. The individual pattern of oncFn/oncTn-C incorporation in the vBM depended on tumour type, vessel size and intratumoural heterogeneity. There was a stratiWcation of the vessel wall showing luminal oncFn and extraluminal oncTn-C depositions. As shown in the xenograft, perivascular oncTn-C is provided by carcinoma cells. In conclusion, tumours diVer in the pattern of Fn or Tn-C isoform positivity in the vessel wall, potentially representing a tumour type speciWc endothelial cell-tumour cell-stromal cell interaction. Carcinoma cells themselves are involved in vascular Tn-C matrix organization. Up to antigen distribution, Fn and Tn-C domain antibodies may serve as vehicles for antiangiogenetic and antiWbrotic agents; oncFn/oncTn-C based targeting should be adapted individually.
Introduction
Carcinoma stroma formation is accompanied by a reorganization of the extracellular matrix (ECM) implying the de novo synthesis of oncofetal isoforms of laminin, Wbronectin and tenascin (Kosmehl et al. 1996; Tlsty and Coussens 2006) . These isoforms, generated by de novo glycosylation, alternative splicing as well as alternative chain assembly are restricted to tumour tissue and are only rarely seen in healthy adult organs. Therefore, oncofetal ECM proteins are suggested as targets for antibody-based tumour imaging and therapy (Ahmed et al. 2008; Hofmeister et al. 2008 ; Kirstein et al. 2006; Tlsty and Coussens 2006) . Indeed, oncofetal splice variants of Wbronectin (Fn) and tenascin-C (Tn-C) are associated with vessel morphogenesis in carcinomas and thus are usable for tumour vascular targeting (Neri and Bicknell 2005) .
Fibronectin (Fn) variants are generated by alternative splicing of the ED-A, ED-B and the IIICS domains as well as by de novo glycosylation (Schwarzbauer 1991) . The Fn isoform containing the ED-B domain (ED-B Fn) is highly expressed in various foetal and tumour tissues and is therefore also known as oncofetal Wbronectin (Berndt et al. 1998; Zardi et al. 1987) . ED-B Fn is also expressed during angioneogenesis both in tumour and in healthy tissues (Astrof and Hynes 2009; Castellani et al. 1994) . Tumour vessels can be selectively targeted in vivo using recombinant ED-B Fn antibodies as carriers for antiangiogenic or proinXammatory drugs in vivo (Borsi et al. 2003; El-Emir et al. 2007; Halin et al. 2002; Nilsson et al. 2001; Sauer et al. 2009; Schliemann et al. 2009; Tarli et al. 1999; Tijink et al. 2009 ). Recently, it could be shown that also antibodies against the ED-A domain eYciently target tumour neovasculature in vivo (Villa et al. 2008) .
Tn-C isofoms are generated by alternative splicing of nine FNIII repeats (A-D) independently omitted or incorporated between the conserved FNIII repeats 5 and 6 in a cell diVerentiation-and maturation-speciWc manner (Bell et al. 1999; Erickson and Inglesias 1984; Ljubimov et al. 1998; Mighell et al. 1997) . Large Tn-C splice variants (Tn-C L ) are preferentially expressed during tissue remodelling processes and are supposed to promote cell migration during tumour-stroma interactions (Lyons and Jones 2007) . A tumour-associated increase in Tn-C L synthesis has been described for several carcinomas Borsi et al. 1992; Hindermann et al. 1999; Katenkamp et al. 2004; Pedretti et al. 2009 ). Tn-C splicing variants diVer in their adhesive properties to cells and also matrix proteins (Chung et al. 1995; Ghert et al. 2001) . Moreover, they have a diVerent susceptibility to matrix metalloproteinases (Cai et al. 2002; Siri et al. 1995) . Furthermore, it has been shown that also Tn-C splicing domains show a diVerent spatial association with vessels in carcinomas . Recently, it could be proven that the splicing domains A1 and C are selectively expressed in vascular Tn-C and that they are good candidates for tumour targeting Silacci et al. 2006) .
A detailed analysis of the diVerential stromal distribution and structural organization of oncofetal Fn and Tn-C variants in relation to tumour vessels and vascular basement membranes (vBM) is not available at the present, but is crucial for the understanding tumour vessel matrix biology and for planning antibody-mediated targeted drug delivery. Therefore, the tissue distribution of ED-A Fn, ED-B Fn, and the Tn-C domains A1 and C was comparatively analysed in selected representative cases of diVerent carcinoma types and in a renal cell carcinoma xenograft using human recombinant biotinylated SIP format antibodies. Furthermore, double and triple immunoXuorescence labelling procedures using biotinylated SIP format antibodies were established and performed to investigate the tissue heterogeneity of tumour vessels concerning Fn and Tn-C splicing domains and their spatial relation to vBM.
Materials and methods

Tissue samples
For immunohistochemical investigations, frozen tissue samples of diVerent carcinoma types were available: clear cell, papillary and chromophobe renal cell carcinoma (RCC), atypical carcinoid of the lung, large cell and squamous cell lung carcinoma, oral squamous cell carcinoma, colon adenocarcinoma, invasive ductal and lobular breast carcinoma, prostatic adenocarcinoma and superWcial as well as invasive urothelial carcinoma of the urinary bladder (UBC). The histological diagnoses were established according to WHO classiWcation criteria and the details of the cases included are given in Table 1 . Ethical approval was obtained from the Local Research Ethic Committee of the Friedrich Schiller University Jena.
To show the contribution of carcinoma cells and endothelial cells to the formation of the vascular oncofetal Wbronectin and tenascin matrix, protein distribution was investigated in a renal cell carcinoma xenograft model. The cells of the renal cell carcinoma cell line A498 were grown in DMEM cell culture medium (Invitrogen GmbH, Karlsruhe, Germany) supplemented with 10% foetal calf serum at 37°C in a humidiWed environment with 5% CO 2 atmosphere. For xenotransplantation, approximately 5 £ 10 6 cells in a physiological NaCl solution were subcutaneously injected into 4 week-old female SCID mice (CB17/Icr-Prkdc<scid>/Crl, Charles River Laboratories, Sulzfeld, Germany). Animal experiments were performed according to the German Law on the Protection of Animals (Reg. No. 02-035/06).
ImmunoXuorescence double and triple staining using biotinylated SIP format antibodies For immunohistochemical detection of the ED-A and ED-B domains of oncofetal Wbronectin (oncFn) and the A1 and C domains of oncofetal tenascin-C (oncTnC), the biotinylated recombinant mini antibodies SIP/F8, SIP/L19, SIP/F16 and SIP/G11 were used. The antibodies were isolated by phage display technology and biotinylated as recently described and the speciWcity as well as restricted tumour reactivity has already been reported in detail (Borsi et al. 2003; Brack et al. 2006; Richter et al. 2009; Silacci et al. 2006; Villa et al. 2008; Viti et al. 1999) .
For immunoXuorescence staining, human tumour and xenograft tissue were immediately shock frozen after the surgical procedure. Cryostat sections were Wxed in icecooled acetone for 10 min. Non-speciWc staining due to endogenous biotin was blocked applying the DAKO Biotin Blocking System according to the instructions of the manufacturer (Dako Deutschland GmbH, Hamburg, Germany). Biotinylated SIP format antibodies were detected using the tyramide-based ampliWcation system TSA™ Kit #22 with HRP: Streptavidin and Alexa Fluor ® 488 tyramide (Invitrogen GmbH, Karlsruhe, Germany) following the recommendations of the manufacturer. Shortly, endogenous peroxidase was blocked with 2% H 2 O 2 /PBS (pH 7.4) followed by an incubation with 1% blocking reagent provided in the kit. Then, the primary SIP antibody (200 ng-1 g/ml in 1% blocking reagent) was allowed to react for 60 min at room temperature followed by streptavidin-peroxidase (diluted 1:100 in 1% blocking reagent) for 45 min. Subsequently, the tyramideAlexa 488 (diluted 1:100 in amplifying buVer with 0.0015% H 2 O 2 ) was applied for 10 min. For immunostaining control, the primary SIP format antibody was omitted. After rinsing in TBS/Tween, sections were mounted with Vectashield H1200 containing DAPI stain (Linaris biologische Produkte GmbH, Wertheim-Bettingen, Deutschland) and sealed with nail polish. ImmunXuorescence was analysed by confocal laser scanning microscopy (CLSM) using a Zeiss microscope (LSM 510, Zeiss, Jena, Germany) equipped with an argon (488 nm) laser combined with the light Wlter LP 505 (Zeiss).
To show the spatial relation of oncFn and oncTn-C variants to vascular structures, a double Xuorescence labelling procedure for the matrix proteins and for CD31 was established. As a Wrst step, the Xuorescence detection of the Fn or Tn-C domains by biotinylated SIP format antibodies was performed using the TSA™ Kit #22 as described above. Then the sections were incubated with the anti-CD31 antibody (clone JC70A, diluted 1:30, Dako Deutschland GmbH, Hamburg, Germany) followed by the detection of bound antibodies with a Cy3 conjugated AYniPure goat anti-mouse IgG (H + L) antiserum (diluted 1:200, dianova Table 1 Summary of the vascular and stromal reactivity pattern of the SIP format antibodies F8, L19, F16 and G11 in the investigated carcinoma cases RCC renal cell carcinoma, SCC squamous cell carcinoma, UBC urothelial carcinoma of the urinary bladder, pv perivascular staining, incl vascular staining as part of the stromal reactivity ¡ = no staining, + = only few marked vessels or spot like stromal deposition, ++ = partial positivity of tumour vessels, moderate stromal positivity, +++ nearly all vessels stained, strong stromal positivity
Ductal adenocarcinoma of the prostate (modiWed grading according to Gleason: 9)
mbH, Hamburg, Germany). In the case of the xenograft tissue, the detection of vascular structures was performed using the rat anti-mouse CD31 antibody MEC13.3 (diluted 1:30, BD Biosciences, Heidelberg, Germany) followed by incubation with a Cy3 conjugated goat anti-rat antiserum (diluted 1:200, dianova mbH, Hamburg, Germany). For immunXuorescence analysis by CLSM, an argon (488 nm) and an HeNe (543 nm) laser were combined with the light Wlters BP 505-550 and LP 560 (Zeiss). Multitrack detection of the Xuorescence emission of both Xuorochromes led to a two-channel image (Manders et al. 1993) . For comparable analysis of Fn and Tn-C domain expression in relation to vascular structures or of the spatial relation of Fn/Tn-C domains to vascular BM in human carcinomas, a triple Xuorescence staining procedure was performed. After Xuorescence detection of the Fn or Tn-C domains using biotinylated SIP format antibodies and the TSA™ Kit #22 as described above, the tissue sections were incubated with a monoclonal anti-Tn-C antibody against the A1/A4 or the B splicing domain (clones BC2 and BC3, diluted 1:50, Balza et al. 1993) or with a monoclonal anti-laminin 4 chain antibody (clone FC10, diluted 1:50, Petäjäniemi et al. 2002) . Bound antibodies were detected using a goat anti-mouse Alexa633 conjugate (diluted 1:200, Invitrogen GmbH, Karlsruhe, Germany). After an additional biotin blocking step (DAKO Biotin Blocking System), a biotinylated anti-CD31 antibody (clone JC70A, diluted 1:30) was applied followed by Cy3 conjugated streptavidin (diluted 1:1,000, Dianova mbH, Hamburg, Germany). The biotinylation of JC70A was performed using the Animal Research Kit (Dako Deutschland GmbH, Hamburg, Germany) according to the manufacturer's instructions. Alternatively, a polyclonal anti-CD31 antiserum was used (diluted 1:400, Zytomed Systems GmbH, Berlin, Germany), which was detected with a Cy3 conjugated AYniPure Goat Anti-Rabbit IgG (H + L) antiserum (diluted 1:200, dianova mbH, Hamburg, Germany). For CLSM, an argon (488 nm), an HeNe1 (543 nm) and an HeNe2 (633 nm) laser were combined with the light Wlters BP 505-530, BP 585-615 and LP 650 (Zeiss). Multitrack detection of the Xuorescence emission led to a three-channel image.
Results
The recombinant SIP format antibodies used in this study are genetically of human origin and lack structures that can be used for detection by secondary reagents commonly applied in "classical" immunostaining protocols. Therefore, we optimized the staining protocols on the basis of biotinylated SIP antibodies. Because tenascin-C splice variants show reduced immunohistochemical expression levels in some carcinoma entities Richter et al. 2009 ), we applied a tyramide-Xuorochrome-based ampliWcation system to detect the biotinylated primary SIP. Using this method, we were able to generate an antibody-speciWc and sensitive tissue labelling using the recombinant antibodies F8, L19, F16 and G11 in the carcinoma samples: the no-primary controls showed no Xuorescence signals. The diVerent staining pattern of the antibodies in terms of histological distribution as well as Xuorescence intensity amongst the investigated carcinoma types, therefore, reXected qualitatively and quantitatively diVerent antigen expression.
Oncofetal Wbronectin and tenascin-C splice variants diVer in stromal deposition and incorporation into the vessel wall amongst carcinoma entities To deWne tissue distribution and association of oncFn and oncTn-C splice variants to tumour vessels, a double immunoXuorescence together with CD31 was performed in selected representative cases of the carcinoma entities listed above. As a result, the investigated carcinomas could be divided into two groups. The Wrst group included the chromophobe, papillary and clear cell RCC as well as the atypical carcinoid of the lung, which showed an almost exclusive vascular deposition, whilst the second group, represented by all the other carcinomas tested, exhibited an extensive stromal deposition including vascular structures. Table 1 summarizes the tissue distribution pattern of the investigated Fn and Tn-C splicing domains in the carcinomas tested so far. Figure 1 gives an overview of the staining patterns in two representative carcinoma types of each group. In the Wrst group, carcinomas that were tested showed diVerences in the vascular decoration with Wbronectin and tenascin-C variants. Whereas the papillary RCC was characterized by a preferential vascular positivity for A1 + and C + tenascin-C (Fig. 1a , e, i, and n), the chromophob RCC showed a more or less exclusive reactivity for the ED-A + Wbronectin antibody F8. The clear cell RCC and the atypical carcinoid of the lung (Fig. 1b, f , k, and o) were characterized by a vascular positivity for ED-A + and ED-B + Wbronectin as well as A1
+ tenascin-C. In the second group, the C domain of Tn-C in general was only rarely expressed. ED-A + Fn, ED-B + Fn and A1 domain containing Tn-C could be detected in most of these carcinomas as strong stromal deposits including CD31-positive vascular structures (Fig. 1c, g , l, p, and d, h, m, q) . In contrast to the invasive UBC, the superWcial UBC revealed only a limited extent of oncofetal Fn and Tn-C expression. As demonstrated by H&E histology (Fig. 1r-u) , diVerences in the stroma positivity for oncofetal Fn and Tn-C corresponded to the extent of desmoplastic stroma reaction.
Tumour vessels showed a heterogenous positivity for oncofetal Wbronectin and tenascin-C variants As a result of CD31/oncFn or oncTn-C double imunoXuorescence labelling, it could be shown that tumour vessels are heterogeneously stained for oncofetal Fn or Tn-C variants. In general, only a part of the CD31-positive vascular structures showed a positivity for oncFn or oncTn-C. Furthermore, as in the case of papillary RCC, tumour vessels could lack oncFn but expressed high amounts of oncTn-C or, as in the case of the atypical carcinoid of the lung, the presence of a strong ED-A Fn and/or ED-B Fn positivity was accompanied by diminished Tn-C reactivity (Fig. 1) . Because of the diYculty in deWning vascular staining pattern in the case of strong stromal deposition of oncofetal Fn or Tn-C variants and the need for the presence of vascular Fn positivity, we focused the structural description of vessel wall positivity of these adhesion proteins to the atypical carcinoid of the lung and the clear cell RCC. Therefore, we performed triple immunoXuorescence staining using recombinant F8 antibody (ED-A Fn reactive) in combination with Tn-C antibodies BC2 (recognizes the domains A1/A4) or BC3 (recognizes the B domain) and a biotinylated CD31 antibody. We were able to show that diVerent types of vessels occurred at least in these carcinomas: (1) CD31-positive vessels lacking ED-A Fn and oncofetal Tn-C, (2) CD31-positive vessels exclusively positive for ED-A Fn or oncofetal Tn-C and (3) CD31-positive vessels enveloped by both matrix proteins investigated (Fig. 2a-c) . Tumour vessel wall showed a stratiWcation concerning oncofetal Wbronectin and tenascin-C variant incorporation
To analyse the structure of the vascular basement membrane (vBM), we performed triple immunoXuorescence staining using the recombinant SIP format antibodies against Fn and Tn-C splicing domains in combination with the anti-laminin 4 chain (Ln 4) antibody FC10 and a biotinylated monoclonal or a polyclonal anti-CD31 antibody. Applying this procedure, we were able to demonstrate a stratiWcation of the vessel wall concerning the incorporation of ED-A or ED-B Fn and A1 or C domain containing Tn-C variants. By confocal laser scanning microscopy, it could be shown that in CD31-positive vessels, the Wbronectins were preferentially localized at the luminal side (Fig. 2d, g ) and the Tn-C variants at the extraluminal side (Fig. 2e, h ) of the Ln 4-positive vBM. StratiWcation of Wbronectins and tenascins was studied additionally by combining the antibodies anti-ED-A Fn (F8), anti-CD31 and anti-Tn-C domains A1/A4 (BC2) or B (BC3), as described above. Again, we could evidence that if both ED-A Fn and oncofetal Tn-C are present in the vessel wall, there is a stratiWed composition of vBM concerning Fn and Tn-C (Fig. 2f, i) . To exclude cross-interaction of detection systems in case of the combination of an SIP antibody, a monoclonal antibody and an ARK biotinylated monoclonal antibody possibly resulting in spurious localization patterns, we performed the analysis with a polyclonal antihuman CD31 antibody in parallel. Although the available polyclonal anti-CD31 antiserum led to a slight background staining of tumour cells, the above described stratiWcation in Fn and Tn BM composition could be proven again (Fig. 2g-i ).
Vascular tenascin-C was provided by carcinoma cells
Because of the deposition of oncofetal tenascin-C extraluminal of the vBM, the question arose if vascular oncTn was provided by the carcinoma cells. For that we compared staining results in the clear cell RCC and an RCC xenograft on SCID mice after transplantation of the human RCC cell line A498 using the recombinant antibodies F8 (EDA Fn), L19 (EDB Fn) (both reactive in mouse and human tissue) and F16 (A1 Tn-C) (only reactive in human). The A498 xenograft exhibited the vascular pattern and histology also seen in clear cell RCC and indeed we found comparable distribution pattern of the investigated oncFn and oncTn-C variants (Fig. 3a-f) . Because of the known species speciWcity of the antibody F16 recognizing only Tn-C (A1) of human origin and the identical staining pattern in the human tumour and the xenograft, at least vascular deposits of Tn-C (A1) in this carcinoma type must be tumour cell derived.
Discussion
Angioneogenesis is known to be a critical step in tumour progression. Understanding the biology of tumour vessels is important for the development and improvement of new angiogenesis-related cancer treatment strategies. De novodeposited angiogenesis-related oncofetal matrix proteins are suitable structures for targeted tumour therapy using human recombinant antibodies as drug carriers (Trachsel and Neri 2006) . Knowledge of the diVerential distribution of these target proteins is crucial for selecting tumour candidates and for planning therapy strategies. Furthermore, it contributes to the understanding of the nature of tumour vasculature. Therefore, we performed a detailed comparative analysis of the tissue and vascular distribution of ED-A Fn, ED-B Fn, A1 domain-containing and C domain-containing large Tn-C recognized by the recombinant SIP antibodies, F8, L19, F16 and G11, in diVerent carcinoma entities. Furthermore, to our knowledge, this is the Wrst report on the description of the structural organization of the vessel wall concerning oncofetal Wbronectin, large tenascin-C and the vascular basement membrane component laminin 4 chain. We were able to show that Fn and Tn-C splice variants are diVerentially expressed amongst diVerent carcinoma entities, qualitatively as well as quantitatively. From our results, there seem to be at least two groups of carcinomas: the Wrst group exhibited a preferentially vascular positivity and the second showed extensive stromal deposits including vascular structures. The two suggested diVerent distribution patterns may strongly be associated with the capability of a tumour to induce a desmoplastic stroma reaction mediated by the expressed cytokine spectrum, the side of tumour growth, as well as the ability to recruit bone marrow-derived endothelial cells and Wbrocytes/myoWbroblasts (Sangai et al. 2005) . Indeed, we could recently show that activated Wbroblasts are a plentiful source of laminins and oncofetal variants of Wbronectin and tenascin-C (Berndt et al. 1998; Berndt et al. 1995; Kosmehl et al. 1995) . Desmoplastic stroma reaction is associated with a poor prognosis in diVerent carcinomas (Caporale et al. 2001; Kellermann et al. 2007; Tsujino et al. 2007) . Based on the knowledge of the crucial role of tumour stroma Wbroblasts in cancer progression, they were suggested to be potential candidates for new molecular treatment strategies (Hofmeister et al. 2008; Ostman and Augsten 2009 ). There are some options to pharmacologically inXuence stroma Wbroblast activation/transdiVerentiation or pericyte development including inhibition of PDGF or TGF-receptor function (Pietras et al. 2002; Tuxhorn et al. 2002) . Furthermore, for tumours with a vascular as well as stromal positivity, a combination of vascular and stromal targeting may exponentiate the therapeutic eVect.
As shown by double immunoXuorescence labelling, there were subsets of tumour vessels characterized by the diVerential inclusion of Wbronectin and tenascin-C variants in the vessel wall indicating a spatial and temporal regulated expression of these Fn and Tn-C isoforms during tumour angioneogenesis. Indeed, there are some reports on a sequential reorganization of ECM molecules during vessel maturation, for instance in the chicken choriallantoic membrane (CAM) capillary bed (Ribatti et al. 2001) or with regard to laminin chains during human foetal angiogenesis (Eble and Niland 2009; Petajaniemi et al. 2002; Sorokin et al. 1997 ). Although we have not examined this in detail, also the diVerential expression of oncofetal Wbronectin and tenascin-C isoforms in the tumour vessel wall may reXect diVerent maturation states of the vessels. This hypothesis is supported by the facts that oncofetal Wbronectin variants, Wbronectin fragments or Wbronectin network organization promote endothelial cell proliferation, vessel formation and recruitment of pericytes or vascular smooth muscle cells (Astrof and Hynes 2009; Zhou et al. 2008) . In contrast, the role of Tn-C is discussed more controversially. Tn-C in general seems to promote endothelial cell migration in neoplastic as well as cardiac pathologies (Astrof and Hynes 2009; Ballard et al. 2006; Orend and Chiquet-Ehrismann 2006; Zagzag et al. 2002) . On the other hand, special Tn-C action may depend on the Tn-C domains included: there are recent reports that the Wbrinogen globe of Tn-C is the active domain promoting a basic Wbroblast growth factor-induced endothelial cell elongation, and that the Tn-C A2 (TNIIIA2) domain inhibits angiogenesis (Saito et al. 2008; Schenk et al. 1999) . Therefore, diVerent biological functions of Tn-C splicing variants during angiogenesis should be considered. Furthermore, the variable Fn and Tn-C expression patterns in diVerent carcinoma types implicate an inXuence of the tumour cells on the expression and organization of vascular ECM proteins. To answer the question if these expression patterns are entity speciWc, further studies must be performed.
To our knowledge, this is the Wrst report on a stratiWed composition of the vascular wall or basement membrane concerning oncofetal Wbronectins and tenascins as well as the laminin 4 chain. We are able to demonstrate that more or less independent of tumour type, ED-A and/or ED-B Fn are localized under the endothelial cells, whereas tenascins can be found at the extraluminal side of the laminin 4 chain positive vBM structure. This pattern may depend on the source of matrix proteins in the ECM of developing tumour vessels. As demonstrated by use of the human reactive A1 Tn-C antibody F16 in an RCC xenograft model, indeed the carcinoma cells are the source of perivascular oncTn-C depositions. In fact, as shown for several carcinoma types, ED-A and ED-B Fn are synthesized and deposited by activated Wbroblasts and endothelial cells, whereas Tn-C variants are abundantly produced by carcinoma cells (Berndt et al. 1998; Hindermann et al. 1999; Katenkamp et al. 2004) . This is also supported by the fact that human umbilical vein endothelial cells cultured on Matrigel or Wbrin gel are positive for F8 and, to a lesser extent, for L19 reactive Wbronectin, but lack positivity for F16 and G11-reactive Tn-C (data not shown). Therefore, the stratiWed vessel wall formation represents the result of endothelial-epithelial interaction during angioneogensis in carcinoma development. The role of Wbroblasts, pericytes, vascular smooth muscle cells or inXammatory cells in the three-dimensional organization of vascular ECM must be elucidated in further studies. However, it could be shown that interaction of carcinoma cells and Wbroblasts leads to a structural reorganization of Fn, Tn-C and Ln networks resulting in multiprotein complexes with altered adhesive properties (Berndt et al. 2001; Franz et al. 2006) or in a modulation of tumour basement membrane composition (Franz et al. 2007 ).
In summary, we were able to show that carcinomas diVer in the distribution pattern and the extent of stromal and vascular deposition of ED-A and ED-B Fn as well as of Tn-C containing the A1 and the C domain. Furthermore, tumours diVer in the pattern of Fn or Tn-C isoform positivity in the vessel wall, potentially representing a tumour type-speciWc endothelial cell-tumour cell-stromal cell interaction. Additionally, we were able to evidence a stratiWed composition of the vascular Fn and Tn-C extracellular matrix. The presented knowledge of diVerential distribution, vascular positivity and stratiWed organization of oncofetal Wbronectins and tenascins is important for a deeper understanding of the biology of tumour vessels and for planning antibodymediated targeted delivery of diagnostic or therapeutic agents using the presented SIP format antibodies. Up to antigen distribution, Fn and Tn-C domain antibodies may serve as vehicles for antiangiogenetic and antiWbrotic agents; oncFn/oncTn-C-based targeting should be adapted individually.
